APO Research
Talk to an analyst

APO RESEARCH · REPORT

Trivalent Inactivated Influenza Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Trivalent Inactivated Influenza Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025180 pages

Choose your research edition.

Industry ResearchTrivalent Inactivated Influenza Vaccine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Trivalent Inactivated Influenza Vaccine Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Trivalent Inactivated Influenza Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Trivalent Inactivated Influenza Vaccine Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Trivalent Inactivated Influenza Vaccine Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Trivalent Inactivated Influenza Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Trivalent Inactivated Influenza Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Trivalent Inactivated Influenza Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Trivalent Inactivated Influenza Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Trivalent Inactivated Influenza Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Trivalent Inactivated Influenza Vaccine include CSL Limited, Sanofi S.A, Serum Institute of India, AstraZeneca, GlaxoSmithKline, Pfizer, Merck, Novartis and Abbott, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Trivalent Inactivated Influenza Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Trivalent Inactivated Influenza Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Trivalent Inactivated Influenza Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Trivalent Inactivated Influenza Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Trivalent Inactivated Influenza Vaccine Segment by Company

CSL Limited

Sanofi S.A

Serum Institute of India

AstraZeneca

GlaxoSmithKline

Pfizer

Merck

Novartis

Abbott

Trivalent Inactivated Influenza Vaccine Segment by Type

Intradermal Injection

Intramuscular Injection

Nasal Spray

Trivalent Inactivated Influenza Vaccine Segment by Application

Public Health Agency

Hospital

Clinic

Others

Trivalent Inactivated Influenza Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Trivalent Inactivated Influenza Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Trivalent Inactivated Influenza Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Trivalent Inactivated Influenza Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Trivalent Inactivated Influenza Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Trivalent Inactivated Influenza Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Trivalent Inactivated Influenza Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Trivalent Inactivated Influenza Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Trivalent Inactivated Influenza Vaccine Industry Trends Table 2. Trivalent Inactivated Influenza Vaccine Industry Drivers Table 3. Trivalent Inactivated Influenza Vaccine Industry Opportunities and Challenges Table 4. Trivalent Inactivated Influenza Vaccine Industry Restraints Table 5. Global Trivalent Inactivated Influenza Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Trivalent Inactivated Influenza Vaccine Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Manufacturers Table 9. Global Trivalent Inactivated Influenza Vaccine Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Trivalent Inactivated Influenza Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Trivalent Inactivated Influenza Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Trivalent Inactivated Influenza Vaccine Manufacturers, Product Type & Application Table 13. Global Trivalent Inactivated Influenza Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Trivalent Inactivated Influenza Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Intradermal Injection Table 17. Major Manufacturers of Intramuscular Injection Table 18. Major Manufacturers of Nasal Spray Table 19. Global Trivalent Inactivated Influenza Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Trivalent Inactivated Influenza Vaccine Sales by Type (2021-2026) & (K Units) Table 21. Global Trivalent Inactivated Influenza Vaccine Sales by Type (2027-2032) & (K Units) Table 22. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Type (2021-2026) Table 23. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Type (2027-2032) Table 24. Global Trivalent Inactivated Influenza Vaccine Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Trivalent Inactivated Influenza Vaccine Revenue by Type (2021-2026) & (K Units) Table 26. Global Trivalent Inactivated Influenza Vaccine Revenue by Type (2027-2032) & (K Units) Table 27. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Type (2021-2026) Table 28. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Public Health Agency Table 30. Major Manufacturers of Hospital Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Others Table 33. Global Trivalent Inactivated Influenza Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Trivalent Inactivated Influenza Vaccine Sales by Application (2021-2026) & (K Units) Table 35. Global Trivalent Inactivated Influenza Vaccine Sales by Application (2027-2032) & (K Units) Table 36. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Application (2021-2026) Table 37. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Application (2027-2032) Table 38. Global Trivalent Inactivated Influenza Vaccine Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Trivalent Inactivated Influenza Vaccine Revenue by Application (2021-2026) & (K Units) Table 40. Global Trivalent Inactivated Influenza Vaccine Revenue by Application (2027-2032) & (K Units) Table 41. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Application (2021-2026) Table 42. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Application (2027-2032) Table 43. Global Trivalent Inactivated Influenza Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Trivalent Inactivated Influenza Vaccine Sales by Region (2021-2026) & (K Units) Table 45. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Region (2021-2026) Table 46. Global Trivalent Inactivated Influenza Vaccine Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Trivalent Inactivated Influenza Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Trivalent Inactivated Influenza Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Trivalent Inactivated Influenza Vaccine Sales by Country (2021-2026) & (K Units) Table 50. North America Trivalent Inactivated Influenza Vaccine Sales by Country (2027-2032) & (K Units) Table 51. Europe Trivalent Inactivated Influenza Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Trivalent Inactivated Influenza Vaccine Sales by Country (2021-2026) & (K Units) Table 53. Europe Trivalent Inactivated Influenza Vaccine Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Trivalent Inactivated Influenza Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Trivalent Inactivated Influenza Vaccine Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Trivalent Inactivated Influenza Vaccine Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Trivalent Inactivated Influenza Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Trivalent Inactivated Influenza Vaccine Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Trivalent Inactivated Influenza Vaccine Sales by Country (2027-2032) & (K Units) Table 60. Global Trivalent Inactivated Influenza Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Trivalent Inactivated Influenza Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Trivalent Inactivated Influenza Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Region (2021-2026) Table 64. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Region (2027-2032) Table 65. CSL Limited Company Information Table 66. CSL Limited Business Overview Table 67. CSL Limited Trivalent Inactivated Influenza Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. CSL Limited Trivalent Inactivated Influenza Vaccine Product Portfolio Table 69. CSL Limited Recent Development Table 70. Sanofi S.A Company Information Table 71. Sanofi S.A Business Overview Table 72. Sanofi S.A Trivalent Inactivated Influenza Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Sanofi S.A Trivalent Inactivated Influenza Vaccine Product Portfolio Table 74. Sanofi S.A Recent Development Table 75. Serum Institute of India Company Information Table 76. Serum Institute of India Business Overview Table 77. Serum Institute of India Trivalent Inactivated Influenza Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Serum Institute of India Trivalent Inactivated Influenza Vaccine Product Portfolio Table 79. Serum Institute of India Recent Development Table 80. AstraZeneca Company Information Table 81. AstraZeneca Business Overview Table 82. AstraZeneca Trivalent Inactivated Influenza Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. AstraZeneca Trivalent Inactivated Influenza Vaccine Product Portfolio Table 84. AstraZeneca Recent Development Table 85. GlaxoSmithKline Company Information Table 86. GlaxoSmithKline Business Overview Table 87. GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Product Portfolio Table 89. GlaxoSmithKline Recent Development Table 90. Pfizer Company Information Table 91. Pfizer Business Overview Table 92. Pfizer Trivalent Inactivated Influenza Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Pfizer Trivalent Inactivated Influenza Vaccine Product Portfolio Table 94. Pfizer Recent Development Table 95. Merck Company Information Table 96. Merck Business Overview Table 97. Merck Trivalent Inactivated Influenza Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Merck Trivalent Inactivated Influenza Vaccine Product Portfolio Table 99. Merck Recent Development Table 100. Novartis Company Information Table 101. Novartis Business Overview Table 102. Novartis Trivalent Inactivated Influenza Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Novartis Trivalent Inactivated Influenza Vaccine Product Portfolio Table 104. Novartis Recent Development Table 105. Abbott Company Information Table 106. Abbott Business Overview Table 107. Abbott Trivalent Inactivated Influenza Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Abbott Trivalent Inactivated Influenza Vaccine Product Portfolio Table 109. Abbott Recent Development Table 110. Key Raw Materials Table 111. Raw Materials Key Suppliers Table 112. Trivalent Inactivated Influenza Vaccine Distributors List Table 113. Trivalent Inactivated Influenza Vaccine Customers List Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Trivalent Inactivated Influenza Vaccine Product Image Figure 2. Global Trivalent Inactivated Influenza Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Trivalent Inactivated Influenza Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Trivalent Inactivated Influenza Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Trivalent Inactivated Influenza Vaccine Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Trivalent Inactivated Influenza Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Intradermal Injection Image Figure 9. Intramuscular Injection Image Figure 10. Nasal Spray Image Figure 11. Global Trivalent Inactivated Influenza Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Trivalent Inactivated Influenza Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Type (2021-2032) Figure 14. Global Trivalent Inactivated Influenza Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Type (2021-2032) Figure 17. Public Health Agency Image Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Others Image Figure 21. Global Trivalent Inactivated Influenza Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Trivalent Inactivated Influenza Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Application (2021-2032) Figure 24. Global Trivalent Inactivated Influenza Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Application (2021-2032) Figure 27. North America Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Trivalent Inactivated Influenza Vaccine Sales Market Share by Country (2021-2032) Figure 29. U.S. Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Trivalent Inactivated Influenza Vaccine Sales Market Share by Country (2021-2032) Figure 34. Germany Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Trivalent Inactivated Influenza Vaccine Sales Market Share by Country (2021-2032) Figure 41. China Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Trivalent Inactivated Influenza Vaccine Sales Market Share by Country (2021-2032) Figure 49. Brazil Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Trivalent Inactivated Influenza Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Trivalent Inactivated Influenza Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Trivalent Inactivated Influenza Vaccine Revenue (2021-2032) & (US$ Million) Figure 60. North America Trivalent Inactivated Influenza Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Trivalent Inactivated Influenza Vaccine Revenue (2021-2032) & (US$ Million) Figure 62. Europe Trivalent Inactivated Influenza Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Trivalent Inactivated Influenza Vaccine Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Trivalent Inactivated Influenza Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Trivalent Inactivated Influenza Vaccine Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Trivalent Inactivated Influenza Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Trivalent Inactivated Influenza Vaccine Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Trivalent Inactivated Influenza Vaccine Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Intradermal Injection
  • Intramuscular Injection
  • Nasal Spray
Applications
  • Public Health Agency
  • Hospital
  • Clinic
  • Others
Companies covered
  • CSL Limited
  • Sanofi S.A
  • Serum Institute of India
  • AstraZeneca
  • GlaxoSmithKline
  • Pfizer
  • Merck
  • Novartis
  • Abbott

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Trivalent Inactivated Influenza Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Trivalent Inactivated Influenza Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Trivalent Inactivated Influenza Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Trivalent Inactivated Influenza Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Trivalent Inactivated Influenza Vaccine Market Dynamics
  1. 2.1 Trivalent Inactivated Influenza Vaccine Industry Trends
  2. 2.2 Trivalent Inactivated Influenza Vaccine Industry Drivers
  3. 2.3 Trivalent Inactivated Influenza Vaccine Industry Opportunities and Challenges
  4. 2.4 Trivalent Inactivated Influenza Vaccine Industry Restraints
3 Trivalent Inactivated Influenza Vaccine Market by Manufacturers
  1. 3.1 Global Trivalent Inactivated Influenza Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Trivalent Inactivated Influenza Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Trivalent Inactivated Influenza Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Trivalent Inactivated Influenza Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Trivalent Inactivated Influenza Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Trivalent Inactivated Influenza Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Trivalent Inactivated Influenza Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Trivalent Inactivated Influenza Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Trivalent Inactivated Influenza Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Trivalent Inactivated Influenza Vaccine Tier 1, Tier 2, and Tier 3
4 Trivalent Inactivated Influenza Vaccine Market by Type
  1. 4.1 Trivalent Inactivated Influenza Vaccine Type Introduction
  2. 4.1.1 Intradermal Injection
  3. 4.1.2 Intramuscular Injection
  4. 4.1.3 Nasal Spray
  5. 4.2 Global Trivalent Inactivated Influenza Vaccine Sales by Type
  6. 4.2.1 Global Trivalent Inactivated Influenza Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Trivalent Inactivated Influenza Vaccine Sales by Type (2021-2032)
  8. 4.2.3 Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Type (2021-2032)
  9. 4.3 Global Trivalent Inactivated Influenza Vaccine Revenue by Type
  10. 4.3.1 Global Trivalent Inactivated Influenza Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Trivalent Inactivated Influenza Vaccine Revenue by Type (2021-2032)
  12. 4.3.3 Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Type (2021-2032)
5 Trivalent Inactivated Influenza Vaccine Market by Application
  1. 5.1 Trivalent Inactivated Influenza Vaccine Application Introduction
  2. 5.1.1 Public Health Agency
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.1.4 Others
  6. 5.2 Global Trivalent Inactivated Influenza Vaccine Sales by Application
  7. 5.2.1 Global Trivalent Inactivated Influenza Vaccine Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Trivalent Inactivated Influenza Vaccine Sales by Application (2021-2032)
  9. 5.2.3 Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Application (2021-2032)
  10. 5.3 Global Trivalent Inactivated Influenza Vaccine Revenue by Application
  11. 5.3.1 Global Trivalent Inactivated Influenza Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Trivalent Inactivated Influenza Vaccine Revenue by Application (2021-2032)
  13. 5.3.3 Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Application (2021-2032)
6 Global Trivalent Inactivated Influenza Vaccine Sales by Region
  1. 6.1 Global Trivalent Inactivated Influenza Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Trivalent Inactivated Influenza Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Trivalent Inactivated Influenza Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Trivalent Inactivated Influenza Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Trivalent Inactivated Influenza Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Trivalent Inactivated Influenza Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Trivalent Inactivated Influenza Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Trivalent Inactivated Influenza Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Trivalent Inactivated Influenza Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Trivalent Inactivated Influenza Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Trivalent Inactivated Influenza Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Trivalent Inactivated Influenza Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Trivalent Inactivated Influenza Vaccine Revenue by Region
  1. 7.1 Global Trivalent Inactivated Influenza Vaccine Revenue by Region
  2. 7.1.1 Global Trivalent Inactivated Influenza Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Trivalent Inactivated Influenza Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Trivalent Inactivated Influenza Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Trivalent Inactivated Influenza Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Trivalent Inactivated Influenza Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Trivalent Inactivated Influenza Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Trivalent Inactivated Influenza Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Trivalent Inactivated Influenza Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Trivalent Inactivated Influenza Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Trivalent Inactivated Influenza Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Trivalent Inactivated Influenza Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 CSL Limited
  2. 8.1.1 CSL Limited Company Information
  3. 8.1.2 CSL Limited Business Overview
  4. 8.1.3 CSL Limited Trivalent Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 CSL Limited Trivalent Inactivated Influenza Vaccine Product Portfolio
  6. 8.1.5 CSL Limited Recent Developments
  7. 8.2 Sanofi S.A
  8. 8.2.1 Sanofi S.A Company Information
  9. 8.2.2 Sanofi S.A Business Overview
  10. 8.2.3 Sanofi S.A Trivalent Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi S.A Trivalent Inactivated Influenza Vaccine Product Portfolio
  12. 8.2.5 Sanofi S.A Recent Developments
  13. 8.3 Serum Institute of India
  14. 8.3.1 Serum Institute of India Company Information
  15. 8.3.2 Serum Institute of India Business Overview
  16. 8.3.3 Serum Institute of India Trivalent Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Serum Institute of India Trivalent Inactivated Influenza Vaccine Product Portfolio
  18. 8.3.5 Serum Institute of India Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca Trivalent Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca Trivalent Inactivated Influenza Vaccine Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
  25. 8.5 GlaxoSmithKline
  26. 8.5.1 GlaxoSmithKline Company Information
  27. 8.5.2 GlaxoSmithKline Business Overview
  28. 8.5.3 GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Product Portfolio
  30. 8.5.5 GlaxoSmithKline Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Trivalent Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Trivalent Inactivated Influenza Vaccine Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Merck
  38. 8.7.1 Merck Company Information
  39. 8.7.2 Merck Business Overview
  40. 8.7.3 Merck Trivalent Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck Trivalent Inactivated Influenza Vaccine Product Portfolio
  42. 8.7.5 Merck Recent Developments
  43. 8.8 Novartis
  44. 8.8.1 Novartis Company Information
  45. 8.8.2 Novartis Business Overview
  46. 8.8.3 Novartis Trivalent Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Novartis Trivalent Inactivated Influenza Vaccine Product Portfolio
  48. 8.8.5 Novartis Recent Developments
  49. 8.9 Abbott
  50. 8.9.1 Abbott Company Information
  51. 8.9.2 Abbott Business Overview
  52. 8.9.3 Abbott Trivalent Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Abbott Trivalent Inactivated Influenza Vaccine Product Portfolio
  54. 8.9.5 Abbott Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Trivalent Inactivated Influenza Vaccine Value Chain Analysis
  2. 9.1.1 Trivalent Inactivated Influenza Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Trivalent Inactivated Influenza Vaccine Production Mode & Process
  6. 9.2 Trivalent Inactivated Influenza Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Trivalent Inactivated Influenza Vaccine Distributors
  9. 9.2.3 Trivalent Inactivated Influenza Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst